A structural shift, not a fad

The wellness industry has weathered plenty of disruptions — keto, fasting, biohacking, "clean" everything. None of them landed with the force of GLP-1s.

A new class of medications — Ozempic, Wegovy, Mounjaro, Zepbound — originally developed for type 2 diabetes is now reshaping how millions of consumers eat, move, and shop. By some industry estimates, more than one in ten US adults has tried a GLP-1 drug, and forecasts suggest the user base will keep climbing for the rest of the decade.

For wellness brands, that's not a fad. It's a structural shift in consumer behavior — and the brands that read it correctly, and finance the pivot well, stand to gain serious ground.

The categories that are getting hit

The first signal showed up in CPG sales data: snacks, sodas, and portion-sized indulgences started slipping. Several major food companies have openly acknowledged that GLP-1 users are eating less and shopping differently. Within wellness, the impact is uneven. Traditional weight-loss supplements — appetite suppressants, thermogenic fat burners, meal replacements — are facing real pressure. So is much of the diet-shake and meal-bar category that historically traded on "feel full longer."

It's a category-by-category reckoning. Whatever a product's pitch was, GLP-1 users are getting "fullness" pharmacologically. Brands whose only job was suppressing appetite are running into a much more effective competitor.

The categories that are growing

On the other side of the shift, several categories are clearly moving the other way.

In short: anything that helps a person eat less and stay healthy at the same time has tailwind. Anything that competed with "eating less" as its core value prop has headwind.

How GLP-1 users actually behave

It's tempting to treat GLP-1 users as a single segment. They aren't. But a few behaviors are consistent enough to plan around.

They buy fewer items per trip, but they're more deliberate about which items they buy. Function and ingredient transparency matter more than marketing polish. They lean heavily on professional advice — primary care, telehealth, dietitians — and they take supplement recommendations from those channels seriously. They're also more willing to spend per unit on products they trust, partly because they're spending less overall on food.

The implication for brands: clean, credible, single-purpose products tend to win shelf space in the GLP-1 basket. Stacks of overlapping claims do not.

Where brands are getting tripped up

The opportunity comes with sharper edges than usual.

The FDA and FTC have both signaled they're watching wellness marketing in this space. Brands that imply their product "works like Ozempic," "supports GLP-1 naturally," or otherwise rides the drug's coattails are inviting regulatory attention — and, in a growing number of cases, are getting it. The safer route is to talk about what the product actually does (supports protein intake, supports hydration, supports digestive comfort) without anchoring the pitch to a prescription drug.

Retailer relationships matter, too. Buyers are being flooded with "GLP-1 companion" pitches, and they can tell the difference between a product that was reformulated for this moment and a relabeling exercise. The brands landing category placements right now are the ones with a real ingredient story, real third-party testing, and real evidence behind their positioning.

The real bottleneck is working capital

Even when brands read the consumer shift correctly, the operational side is where most of them get stuck — and the choke point is almost always working capital.

A few patterns we're seeing across the GLP-1-impacted wellness category:

Demand outpaces financing cycles

A SKU that was a steady performer for three years can double its velocity in a quarter once it gets pulled into the GLP-1 basket. Inventory plans built on last year's velocity miss, and brands run out of stock right when retailers are willing to expand placement.

Suppliers want more money up front

Capacity for protein isolate, specialty fibers, electrolytes, and key micronutrients has tightened. Co-manufacturers and ingredient suppliers are quoting longer lead times and asking for larger deposits — sometimes 30–50% — before they'll schedule a run.

Retailer payment terms haven't gotten friendlier

Net-60 and net-90 are still the norm, and a few of the larger national chains stretch further. Brands are paying suppliers months before retailers pay them, and the gap widens every time volume grows.

Category exits create stranded inventory

Products that lost their fit with GLP-1 consumers tie up cash on shelves and in 3PLs. Liquidating that inventory is slow, and the proceeds rarely cover what the brand needs to fund the growing SKUs.

Add it up and the math is brutal: the brands with the strongest tailwinds are often the ones running tightest on cash, because every win requires writing a bigger check before a single retailer payment comes in.

How Alethium supports brands through the shift

Alethium was built for exactly this kind of moment — when consumer behavior moves faster than a brand's balance sheet can keep up.

We work with wellness brands to finance the trade cycle that sits between a confirmed purchase order and a paid retailer invoice. In practice, that means:

Why this matters now

Because we underwrite the trade cycle — purchase orders, inventory, receivables — rather than the brand's historical EBITDA, growth in a category is treated as an asset, not a risk flag.

That's the part traditional bank lines tend to miss right now: the brands that need capital most are exactly the ones whose last 12 months of financials don't yet reflect where the category is going.

What to do about it

The GLP-1 wave isn't going away, and the brands that adapt earliest will have the easiest time. A few practical moves:

The wellness brands that come out of this stronger will be the ones that treated GLP-1s not as a threat to their old playbook, but as a signal to write a new one — and built the capital structure to fund it.